Fresenius/€FRE
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Fresenius
Fresenius SE & Co. KGaA, operating under the ticker FRE, is a global healthcare group founded in 1912. The company specializes in products and services for dialysis, hospitals, and outpatient medical care. Operating in the healthcare sector, Fresenius provides a range of services including engineering and services for hospitals and other healthcare facilities.
Ticker
€FRE
Sector
Primary listing
XETRA
Employees
176,207
Headquarters
Website
Fresenius Metrics
BasicAdvanced
€27B
23.79
€2.00
1.01
€1.00
2.10%
Price and volume
Market cap
€27B
Beta
1.01
52-week high
€48.06
52-week low
€31.60
Average daily volume
45K
Dividend rate
€1.00
Financial strength
Current ratio
1.312
Quick ratio
0.637
Long term debt to equity
55.939
Total debt to equity
67.849
Dividend payout ratio (TTM)
58.31%
Interest coverage (TTM)
3.79%
Profitability
EBITDA (TTM)
2,610
Gross margin (TTM)
24.28%
Net profit margin (TTM)
5.05%
Operating margin (TTM)
8.41%
Effective tax rate (TTM)
28.97%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
2.76%
Return on equity (TTM)
5.83%
Valuation
Price to earnings (TTM)
23.786
Price to revenue (TTM)
1.201
Price to book
1.46
Price to tangible book (TTM)
18.4
Price to free cash flow (TTM)
21.65
Free cash flow yield (TTM)
4.62%
Free cash flow per share (TTM)
2.194
Dividend yield (TTM)
2.10%
Forward dividend yield
2.10%
Growth
Revenue change (TTM)
4.32%
Earnings per share change (TTM)
-200.90%
3-year revenue growth (CAGR)
-9.21%
10-year revenue growth (CAGR)
-1.51%
3-year earnings per share growth (CAGR)
-11.55%
10-year earnings per share growth (CAGR)
-0.73%
3-year dividend per share growth (CAGR)
2.82%
10-year dividend per share growth (CAGR)
8.56%
What the Analysts think about Fresenius
Analyst ratings (Buy, Hold, Sell) for Fresenius stock.
Bulls say / Bears say
Fresenius has raised its 2025 organic revenue growth target to 5–7%, up from 4–6%, and reported Q2 EBIT of €654 million, beating analysts’ consensus by 2.6%, reflecting strong demand in its main businesses and successful restructuring efforts. (Reuters)
For Q1 2025, Fresenius recorded EBIT of €654 million, above the Vara Research consensus of €634 million, driven by strong results from its Fresenius Kabi pharmaceutical unit and strengthening confidence in its full-year outlook. (Reuters)
Proceeds from a planned proportional sale of €1 billion in Fresenius Medical Care shares, to maintain a roughly 28.6% stake, will be reinvested as part of the #FutureFresenius strategy in high-growth areas such as Fresenius Kabi and hospital operator Helios, aiming for better capital efficiency. (Reuters)
Fresenius Medical Care’s Q2 earnings fell short of expectations, with U.S. same-market dialysis treatment growth stagnating and full-year guidance lowered to flat or only slightly positive, highlighting Fresenius’s dependence on the volatile dialysis business. (Reuters)
A roughly 10% appreciation of the euro since March 2025 is projected to reduce earnings by 2–3% for export-focused companies such as Fresenius, putting pressure on global competitiveness and margins. (Reuters)
In the wake of FMC’s Q2 earnings miss, its share price dropped around 4%, implying Fresenius could face mark-to-market losses on its planned share sale to maintain its stake, potentially limiting available funds for key investments. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Fresenius Financial Performance
Revenues and expenses
Fresenius Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fresenius stock?
Fresenius (FRE) has a market cap of €27B as of September 18, 2025.
What is the P/E ratio for Fresenius stock?
The price to earnings (P/E) ratio for Fresenius (FRE) stock is 23.79 as of September 18, 2025.
Does Fresenius stock pay dividends?
Yes, the Fresenius (FRE) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is €1 and the yield is 2.1%. Fresenius has a payout ratio of 58.31% on a trailing twelve-month basis.
When is the next Fresenius dividend payment date?
The next Fresenius (FRE) dividend payment date is unconfirmed.
What is the beta indicator for Fresenius?
Fresenius (FRE) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.